General Information:

Id: 391
Diseases: Amyotrophic lateral sclerosis
Mus musculus
SOD1(G93A) transgenic mouse
BTO:0001279 spinal cord; BTO:0000312 motoneuron
article
Reference: Kiaei M et al.(2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurosci. 26: 2467-2473 [PMID: 16510725]

Interaction Information:

Comment There is an increase of TNF-alpha and FasL immunoreactivity in lumbar spinal cord sections of ALS patients and G93A transgenic mice. At 60 d, motor neurons from G93A mice with a healthy appearance were stained with TNF-alpha moderately, and immunoreactivity became more intense at 90 and 110 d.
Formal Description
Interaction-ID: 1608

gene/protein mutant

SOD1-p.G93A

increases_quantity of

gene/protein

TNF

in spinal cord motor neurons; especially at stage 90-110 days
Drugbank entries Show/Hide entries for TNF
Comment FasL immunostaining was found in both neurons and astrocytes similar to TNF-alpha. The increase of FasL immunoreactivity in G93A SOD1 mice occurred as early as 60 days.
Formal Description
Interaction-ID: 1613

gene/protein mutant

SOD1-p.G93A

increases_quantity of

gene/protein

FASLG

in spinal cord motor neurons; as early as 60 days
Comment Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord.
Formal Description
Interaction-ID: 1621

gene/protein mutant

SOD1-p.G93A

increases_activity of

in spinal cord motor neurons
Comment Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord.
Formal Description
Interaction-ID: 1623

drug/chemical compound

Thalidomide

decreases_activity of

in spinal cord motor neurons; in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Thalidomide
Comment Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord.
Formal Description
Interaction-ID: 1625

drug/chemical compound

Lenalidomide

decreases_activity of

in spinal cord motor neurons; in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Lenalidomide
Comment TNF-alpha mRNA was increased 10-fold in G93A SOD1 mice compared with control littermates. Thalidomide and lenalidomide treatment reduced TNF-alpha mRNA significantly.
Formal Description
Interaction-ID: 1626

gene/protein mutant

SOD1-p.G93A

increases_expression of

gene/protein

TNF

in spinal cord motor neurons
Drugbank entries Show/Hide entries for TNF
Comment TNF-alpha mRNA was increased 10-fold in G93A SOD1 mice compared with control littermates. Thalidomide and lenalidomide treatment reduced TNF-alpha mRNA significantly.
Formal Description
Interaction-ID: 1635

drug/chemical compound

Thalidomide

decreases_expression of

gene/protein

TNF

in spinal cord motor neurons; in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Thalidomide or TNF
Comment TNF-alpha mRNA was increased 10-fold in G93A SOD1 mice compared with control littermates. Thalidomide and lenalidomide treatment reduced TNF-alpha mRNA significantly.
Formal Description
Interaction-ID: 1636

drug/chemical compound

Lenalidomide

decreases_expression of

gene/protein

TNF

in spinal cord motor neurons; in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Lenalidomide or TNF
Comment IL-1alpha RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in lenalidomide-treated G93A mice while unchanged in thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1672

gene/protein mutant

SOD1-p.G93A

increases_expression of

gene/protein

IL1A

in spinal cord; at 110 days of age
Comment IL-1alpha RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in lenalidomide-treated G93A mice while unchanged in thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1676

drug/chemical compound

Lenalidomide

decreases_expression of

gene/protein

IL1A

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Lenalidomide
Comment IL-1alpha RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in lenalidomide-treated G93A mice while unchanged in thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1677

drug/chemical compound

Thalidomide

NOT affects_expression of

gene/protein

IL1A

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Thalidomide
Comment IL-1beta RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced by lenalidomide but not thalidomide treatment.
Formal Description
Interaction-ID: 1685

gene/protein mutant

SOD1-p.G93A

increases_expression of

gene/protein

IL1B

in spinal cord; at 110 days of age
Drugbank entries Show/Hide entries for IL1B
Comment IL-1beta RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced by lenalidomide but not thalidomide treatment.
Formal Description
Interaction-ID: 1686

drug/chemical compound

Lenalidomide

decreases_expression of

gene/protein

IL1B

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Lenalidomide or IL1B
Comment IL-1beta RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced by lenalidomide but not thalidomide treatment.
Formal Description
Interaction-ID: 1687

drug/chemical compound

Thalidomide

NOT affects_expression of

gene/protein

IL1B

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Thalidomide or IL1B
Comment IL-12p40 RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in both lenalidomide- and thalidomide- treated G93A mice.
Formal Description
Interaction-ID: 1688

gene/protein mutant

SOD1-p.G93A

increases_expression of

gene/protein

IL12B

in spinal cord; at 110 days of age
Drugbank entries Show/Hide entries for IL12B
Comment IL-12p40 RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in both lenalidomide- and thalidomide- treated G93A mice.
Formal Description
Interaction-ID: 1689

drug/chemical compound

Lenalidomide

decreases_expression of

gene/protein

IL12B

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Lenalidomide or IL12B
Comment IL-12p40 RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly reduced in both lenalidomide- and thalidomide- treated G93A mice.
Formal Description
Interaction-ID: 1690

drug/chemical compound

Thalidomide

decreases_expression of

gene/protein

IL12B

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Thalidomide or IL12B
Comment IL-1RA RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1691

gene/protein mutant

SOD1-p.G93A

increases_expression of

gene/protein

IL1RN

in spinal cord; at 110 days of age
Comment IL-1RA RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1692

drug/chemical compound

Lenalidomide

increases_expression of

gene/protein

IL1RN

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Lenalidomide
Comment IL-1RA RNA was elevated in vehicle-treated G93A mice compared with wild type (N1020 controls) and significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1693

drug/chemical compound

Thalidomide

increases_expression of

gene/protein

IL1RN

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Thalidomide
Comment TGF-beta1 RNA was not changed significantly in vehicle-treated G93A mice compared with wild type (N1020 controls) but significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1695

gene/protein mutant

SOD1-p.G93A

NOT affects_expression of

gene/protein

TGFB1

in spinal cord; at 110 days of age
Drugbank entries Show/Hide entries for TGFB1
Comment TGF-beta1 RNA was not changed significantly in vehicle-treated G93A mice compared with wild type (N1020 controls) but significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1696

drug/chemical compound

Lenalidomide

increases_expression of

gene/protein

TGFB1

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Lenalidomide or TGFB1
Comment TGF-beta1 RNA was not changed significantly in vehicle-treated G93A mice compared with wild type (N1020 controls) but significantly elevated further in both lenalidomide- and thalidomide-treated G93A mice.
Formal Description
Interaction-ID: 1697

drug/chemical compound

Thalidomide

increases_expression of

gene/protein

TGFB1

in spinal cord; in SOD1(G93A) transgenic mice at 110 days of age
Drugbank entries Show/Hide entries for Thalidomide or TGFB1
Comment Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord.
Formal Description
Interaction-ID: 15553

drug/chemical compound

Thalidomide

decreases_activity of

disease

Amyotrophic lateral sclerosis

in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Thalidomide
Comment Treatment with either thalidomide or lenalidomide attenuated weight loss, enhanced motor performance, decreased motor neuron cell death, and significantly increased the life span in G93A transgenic mice. Treated G93A mice showed a reduction in TNF-alpha and FasL immunoreactivity as well as their mRNA in the lumbar spinal cord.
Formal Description
Interaction-ID: 15554

drug/chemical compound

Lenalidomide

decreases_activity of

disease

Amyotrophic lateral sclerosis

in SOD1(G93A) transgenic mice
Drugbank entries Show/Hide entries for Lenalidomide